Abstract
Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians. Optimal care can require multidisciplinary effort by pulmonologists, medical oncologists, and radiologists, and awareness of the possibility of treatment-induced pulmonary toxicity by emergency department and primary care physicians. This Viewpoint gives an overview of the diagnosis and management of pulmonary toxicity arising from cancer immunotherapy, including widely used treatments, such as immune checkpoint inhibitors, and emerging therapies, such as chimeric antigen receptor T cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 472-478 |
| Number of pages | 7 |
| Journal | The Lancet Respiratory Medicine |
| Volume | 6 |
| Issue number | 6 |
| DOIs |
|
| State | Published - Jun 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. / Rashdan, Sawsan; Minna, John D.; Gerber, David E.
In: The Lancet Respiratory Medicine, Vol. 6, No. 6, 01.06.2018, p. 472-478.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
AU - Rashdan, Sawsan
AU - Minna, John D.
AU - Gerber, David E.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians. Optimal care can require multidisciplinary effort by pulmonologists, medical oncologists, and radiologists, and awareness of the possibility of treatment-induced pulmonary toxicity by emergency department and primary care physicians. This Viewpoint gives an overview of the diagnosis and management of pulmonary toxicity arising from cancer immunotherapy, including widely used treatments, such as immune checkpoint inhibitors, and emerging therapies, such as chimeric antigen receptor T cells.
AB - Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians. Optimal care can require multidisciplinary effort by pulmonologists, medical oncologists, and radiologists, and awareness of the possibility of treatment-induced pulmonary toxicity by emergency department and primary care physicians. This Viewpoint gives an overview of the diagnosis and management of pulmonary toxicity arising from cancer immunotherapy, including widely used treatments, such as immune checkpoint inhibitors, and emerging therapies, such as chimeric antigen receptor T cells.
UR - http://www.scopus.com/inward/record.url?scp=85047431568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047431568&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(18)30172-3
DO - 10.1016/S2213-2600(18)30172-3
M3 - Comment/debate
VL - 6
SP - 472
EP - 478
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
SN - 2213-2600
IS - 6
ER -